Every year, over 2.75 million people in the EU alone are diagnosed with cancer, and cases are rising. The good news is that advances in treatments mean that survival rates are improving dramatically.
In line with Europe’s Beating Cancer Plan and the EU Mission Cancer, IHI and IMI projects are investigating the complexities of cancer biology, enhancing cancer prevention measures, figuring out how to diagnose patients earlier, optimising treatments, and researching how to improve patients’ quality of life.
Our projects engage cross-sectoral and multidisciplinary approaches to deliver results from diagnosis to cure, and we tackle 14 different cancer indications from lung, colorectal, breast and prostate cancer, which are the most commonly diagnosed cancers in the EU, to rarer cancers such as brain and blood cancers which are the most common types of childhood cancer.
To date, IMI and IHI have funded 22 cancer projects to the tune of €480 million of public and private investments addressing various aspects of the prevention, diagnosis and treatment of cancer.
During this event, we will explore some of the highlights from several IHI and IMI projects focused on cancer:
- PIONEER used big data to address key knowledge gaps related to the screening, diagnosis and treatment of prostate cancer patients.
- OPTIMA is harnessing the power of AI to advance treatments and facilitate decision-making for physicians and patients with prostate, breast and lung cancer.
- CANCER-ID advanced the science that will lead to more widespread use of liquid biopsy (a blood test that detects signs of cancerous tumors, including tumor cells and cancer cell DNA in the blood) in clinical trials of cancer drugs, and in the clinical treatment of patients with cancer.
- GUIDE-MRD is exploring how blood tests could be used to identify which patients might benefit from additional treatment, and which patients would likely not benefit from treatment.
- IMAGIO, a new IHI project that focuses on ‘interventional oncology’, which uses miniaturised instruments to target cancer cells more precisely, thereby sparing health cells.
PIONEER & OPTIMA Project Coordinator
Professor of Urological Surgery
University of Aberdeen
IMAGIO Project Coordinator
Manager Public Private Partnerships
Philips Image Guided Therapy
PIONEER Project Industry Lead
Medical Advisor & General Manager EAU UroEvidenceHub
European Association of Urology
Bayer AG
IMAGIO PhD Candidate
Leiden University Medical Center
GUIDE.MRD Project Coordinator
Director, Professor of Medicine
Chairman of European Liquid Biopsy Society
University Medical Center Hamburg-Eppendorf
_2.png "title")
Scientific Officer
Innovative Health Initiative